IP Library › Granted Patent US 11,104,967
Granted Patent B2
US 11,104,967 · App. 16/521,371 · Granted Aug 31, 2021

Evolution of site-specific recombinases

Inventors: David R. Liu (Lexington, MA); David B. Thompson (Brookline, MA); Jeffrey L. Bessen (Somerville, MA)
Assignee: President and Fellows of Harvard College
C12Y207/07C12N9/1241C12N15/1037C12N15/1058C12N15/1093C12N15/86C12Q1/6876C40B30/04C12N15/907C12N2795/00021C12N2795/00043C12N2795/14121C12N2795/14143C40B40/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,104,967
App. No.
16/521,371
Filed
Jul 24, 2019
Granted
Aug 31, 2021
Kind
B2
Art Unit
1639
USPC
506/9
Abstract

Some aspects of the present disclosure provide methods for evolving recombinases to recognize target sequences that differ from the canonical recognition sequences. Some aspects of this disclosure provide evolved recombinases, e.g., recombinases that bind and recombine naturally-occurring target sequences, such as, e.g., target sequences within the human Rosa26 locus. Methods for using such recombinases for genetically engineering nucleic acid molecules in vitro and in vivo are also provided. Some aspects of this disclosure also provide libraries and screening methods for assessing the target site preferences of recombinases, as well as methods for selecting recombinases that bind and recombine a non-canonical target sequence with high specificity.

Claims (12)

1. A method for evolving a recombinase, the method comprising (a) contacting a population of host cells with a population of phage vectors comprising a gene encoding a recombinase and deficient in at least one gene for the generation of infectious phage particles, wherein (1) the host cells are amenable to transfer of the phage vector; (2) the vector allows for expression of the recombinase in a host cell, can be replicated by the host cell, and the replicated vector can transfer from host cell to host cell; (3) the host cells express a gene product encoded by the at least one gene for the generation of infectious phage particles of (a) in response to the recombination of a recombinase target sequence by the recombinase, and the level of gene product expression depends on the activity of the recombinase towards the target sequence; (b) incubating the population of host cells under conditions allowing for mutation of the gene encoding the recombinase and the transfer of the phage vectors from host cell to host cell, wherein host cells are removed from the host cell population, and the population of host cells is replenished with fresh host cells that do not harbor the phage vector; (c) isolating a replicated phage vector from the host cell population in (b), wherein the replicated vector comprises a mutated version of the gene encoding the recombinase,

wherein the host cells harbor an expression construct comprising a nucleotide sequence encoding a gene product of the at least one gene for the generation of infectious phage particles of (a) under the control of a heterologous promoter and a transcriptional terminator flanked by two recombinase target sequences, wherein the recombinase target sequences are different from the target sequences recognized by the wild-type version of the recombinase, wherein recombination of the recombinase target sequences results in excision of the transcriptional terminator and expression of the at least one gene for the generation of infectious phage particles,

wherein the phage vector is a filamentous phage, wherein the phage vector is an M13 phage, an fl phage, or an fd phage, wherein the at least one gene for the generation of infectious phage particles comprises a sequence encoding a pIII protein.

2. The method of claim 1 , wherein the recombinase is a Cre recombinase.

3. The method of claim 1 , wherein the replicated vector isolated in (c) encodes a mutated recombinase that cleaves the recombinase target sequence with higher efficiency than the version of the recombinase of (a).

4. The method of claim 1 , wherein the recombinase target sequence comprises a sequence occurring in the Rosa 26 locus of the target cell.

5. The method of claim 1 , wherein the recombinase target sequence comprises a sequence occurring in a genomic locus that is expressed only in cells associated with a disease or disorder.

6. The method of claim 1 , wherein the host cells comprise an accessory plasmid, and together the phage vector of (a) and the accessory plasmid comprise all genes required for the generation of an infectious phage.

7. The method of claim 1 , wherein the method further comprises a negative selection for undesired recombinase activity.

8. The method of claim 7 , wherein the host cells comprise an expression construct encoding a dominant-negative pIII protein (pIII-neg), and wherein the expression of the pIII-neg protein depends on the undesired recombinase activity.

9. The method of claim 8 , wherein expression of the pIII-neg protein is activated by recombination of undesired recombinase target sequences flanking a transcriptional terminator within the expression construct encoding the pIII-neg protein.

10. The method of claim 1 , wherein the host cells further comprise a mutagenesis plasmid.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2019
From: LIU, DAVID R.
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 050440/0492 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2019
From: HOWARD HUGHES MEDICAL INSTITUTE
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 050440/0512 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2019
From: BESSEN, JEFFREY L.; THOMPSON, DAVID B.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 050440/0525 →
Continuity (3)
Division 15216844 · Jul 22, 2016
Provisional Application 62195739 · Jul 22, 2015
Related Publication 20200071722A1 · Mar 5, 2020
Cited By (4)
US 12,366,009 US 12,378,539 US 12,398,390 US 12,655,182